5 financing rounds recorded. Largest: GR3N's series b of EUR 15.5M.
The two largest deals are 79% of the month's capital, so the total describes a handful of companies rather than the market.
1 of 5 rounds were pre-seed or seed, and together they drew 11% of the capital. The formation end is busy and cheap.
1 of 5 rounds came out of an institution (ETH Zurich 1), which is the structural feature of this market rather than a feature of the month.
18 distinct investors were named across 4 rounds, none of them twice. No fund built a visible position this month.
1 transaction is announced rather than closed and its figure is excluded from every total above: Prem (USD 100M, raising, expected to close in Q3). A ceiling quoted gross, before redemptions and subject to approval, is not capital raised.
2 of 4 closed rounds have been checked against a primary source, covering CHF 26M of the CHF 33M, 79%. The rest is as reported. Every error found in this database so far was a figure or a label that a primary source contradicted, so that share is the weight this page can carry.
| Company | Sector | Stage | Raised | Investors | HQ |
|---|---|---|---|---|---|
| Prem | AI | Series Aannounced | raising USD 100M | – | Lugano |
| GR3N | Cleantech | Series B | EUR 15.5M | 360 Capital, VP Textile | Chiasso |
| Nanoflex Robotics | MedTech | Grant | Blended: EUR 2.5M grant plus EUR 10M equity investment from the EIC Fund EUR 12.5M | European Innovation Council, EIC Fund | Glattbrugg |
| Talentir | FinTech | Seed | EUR 4M | Redstone, Inovia Capital, Patrick Pichette, Raif Jacobs, Sha | CH |
| AC Immune SA | Biotech | Grant | USD 4M | Innosuisse | Lausanne |
| Grant | 2 | CHF 14.8M |
| Series B | 1 | CHF 14.4M |
| Seed | 1 | CHF 3.7M |
| Series A | 1 | – |
| Cleantech | 1 | CHF 14.4M |
| MedTech | 1 | CHF 11.6M |
| FinTech | 1 | CHF 3.7M |
| Biotech | 1 | CHF 3.2M |
| AI | 1 | – |
| Chiasso | 1 | CHF 14.4M |
| Glattbrugg | 1 | CHF 11.6M |
| not stated | 1 | CHF 3.7M |
| Lausanne | 1 | CHF 3.2M |
| Lugano | 1 | – |